Key result
Concomitant treatment with proton pump inhibitors did not attenuate the antiplatelet effect of clopidogrel across 5 platelet function tests in patients on dual antiplatelet therapy.
Why the study?
Does concomitant proton pump inhibitor therapy attenuate the antiplatelet effect of clopidogrel in patients on dual antiplatelet therapy after angioplasty and stenting?
Observational (n=230)
Does concomitant proton pump inhibitor therapy attenuate the antiplatelet effect of clopidogrel in patients on dual antiplatelet therapy after angioplasty and stenting?
Concomitant use of proton pump inhibitors does not significantly attenuate the antiplatelet efficacy of clopidogrel in patients undergoing angioplasty and stenting, regardless of the PPI type or platelet function assay used.
Answers are grounded in this paper and cite their sources.
May support PPI co-prescription with clopidogrel; leaves open translation to clinical outcomes in stented patients.
Proton pump inhibitors (PPIs) are metabolized by the cytochrome P450 enzyme system to a variable degree and may therefore interact with the metabolism of clopidogrel to its active form. The conflicting data on this potential interaction may be due to the use of different PPIs and platelet function tests in recent studies. We therefore evaluated the influence of different PPIs on the antiplatelet effect of clopidogrel by 5 platelet function tests in the same population. Adenosine diphosphate (ADP)-inducible platelet reactivity was assessed in 230 patients on dual antiplatelet therapy after angioplasty and stenting for cardiovascular disease by the light transmission aggregometry, VerifyNow P2Y12 assay, vasodilator-stimulated phosphoprotein phosphorylation assay, multiple electrode aggregometry, and Impact-R. ADP-inducible platelet reactivity showed no significant differences between patients without (n = 95, 41.3%) and with PPI therapy (n = 135, 58.7%) in each test system (all P > 0.05). Furthermore, we observed no significant differences of ADP-inducible platelet reactivity between patients without PPIs and patients with pantoprazole (n = 95, 70.4%), esomeprazole (n = 22, 16.3%), omeprazole (n = 9, 6.65%), or lansoprazole (n = 9, 6.65%) (all P > 0.3). High on-treatment residual ADP-inducible platelet reactivity occurred to a similar extent in patients without and with PPI therapy in each assay (all P > 0.05). In conclusion, concomitant treatment with PPIs did not attenuate the antiplatelet effect of clopidogrel in patients on dual antiplatelet therapy irrespective of the type of PPI and the used test system.
No takes yet. Share an insight, caveat, or question.
Gremmel et al. (2010) conducted an observational in Cardiovascular disease (n=230). Proton pump inhibitors (PPIs) vs. No PPI therapy was evaluated on ADP-inducible platelet reactivity (p=>0.05). Concomitant treatment with proton pump inhibitors did not attenuate the antiplatelet effect of clopidogrel across 5 platelet function tests in patients on dual antiplatelet therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: